Summit Therapeutics (SMMT) EBIAT: 2016-2025
Historic EBIAT for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to -$231.8 million.
- Summit Therapeutics' EBIAT fell 312.05% to -$231.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$921.6 million, marking a year-over-year decrease of 368.59%. This contributed to the annual value of -$221.3 million for FY2024, which is 64.01% up from last year.
- Latest data reveals that Summit Therapeutics reported EBIAT of -$231.8 million as of Q3 2025, which was up 59.03% from -$565.7 million recorded in Q2 2025.
- Summit Therapeutics' 5-year EBIAT high stood at -$19.2 million for Q4 2022, and its period low was -$565.7 million during Q2 2025.
- Its 3-year average for EBIAT is -$126.6 million, with a median of -$60.4 million in 2024.
- Per our database at Business Quant, Summit Therapeutics' EBIAT climbed by 0.55% in 2023 and then tumbled by 836.84% in 2025.
- Quarterly analysis of 4 years shows Summit Therapeutics' EBIAT stood at -$19.2 million in 2022, then slumped by 90.17% to -$36.6 million in 2023, then slumped by 67.37% to -$61.2 million in 2024, then slumped by 312.05% to -$231.8 million in 2025.
- Its EBIAT was -$231.8 million in Q3 2025, compared to -$565.7 million in Q2 2025 and -$62.9 million in Q1 2025.